user

PRECLINICAL STUDIES OF THE PARP INHIBITOR OLAPARIB IN COMBINATION WITH IMATINIB IN BRCA STRATIFIED OVARIAN CANCER

被引：0
|
作者：
Matheson, E. [1 ]
Salehan, M. [1 ]
Mukhopadhyay, A. [1 ]
Curtin, N. J. [1 ]
Drew, Y. [1 ]
机构：
[1] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2016年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
IGCS-0943
引用
收藏
页码：673 / 673
页数：1
相关论文
共 50 条
  • [1] Preclinical evaluation of olaparib and metformin combination in BRCA1 wildtype ovarian cancer
    Hijaz, M.
    Chhina, J.
    Mert, I.
    Taylor, M.
    Dar, S.
    Al-Wahab, Z.
    Ali-Fehmi, R.
    Buekers, T.
    Munkarah, A. R.
    Rattan, R.
    [J]. GYNECOLOGIC ONCOLOGY, 2016, 142 (02) : 323 - 331
  • [2] Olaparib: a promising PARP inhibitor in ovarian cancer therapy
    Ying Chen
    Lei Zhang
    Quan Hao
    [J]. Archives of Gynecology and Obstetrics, 2013, 288 : 367 - 374
  • [3] Olaparib: a promising PARP inhibitor in ovarian cancer therapy
    Chen, Ying
    Zhang, Lei
    Hao, Quan
    [J]. ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2013, 288 (02) : 367 - 374
  • [4] Olaparib, PARP1 inhibitor in ovarian cancer
    Marchetti, Claudia
    Imperiale, Ludovica
    Gasparri, Maria Luisa
    Palaia, Innocenza
    Pignata, Sandro
    Boni, Terenzio
    Bellati, Filippo
    Panici, Pierluigi Benedetti
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (10) : 1575 - 1584
  • [5] Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer
    Lin, Z. Ping
    Zhu, Yong-Lian
    Lo, Ying-Chun
    Moscarelli, Jake
    Xiong, Amy
    Korayem, Yasmin
    Huang, Pamela H.
    Giri, Smith
    LoRusso, Patricia
    Ratner, Elena S.
    [J]. PLOS ONE, 2018, 13 (11):
  • [6] Pediatric preclinical evaluation of the PARP inhibitor olaparib
    Norris, Robin E.
    Adamson, Peter C.
    Fox, Elizabeth
    [J]. CANCER RESEARCH, 2011, 71
  • [7] Preclinical Evaluation of the PARP Inhibitor, Olaparib, in Combination With Cytotoxic Chemotherapy in Pediatric Solid Tumors
    Norris, Robin E.
    Adamson, Peter C.
    Nguyen, Vu T.
    Fox, Elizabeth
    [J]. PEDIATRIC BLOOD & CANCER, 2014, 61 (01) : 145 - 150
  • [8] Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
    Ivy, S. Percy
    Liu, Joyce F.
    Lee, Jung-Min
    Matulonis, Ursula A.
    Kohn, Elise C.
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2016, 25 (05) : 597 - 611
  • [9] Preclinical evaluation of the ATR inhibitor VE-821 alone and in combination with the PARP inhibitor olaparib in neuroblastoma
    Southgate, H.
    Chen, L.
    Curtin, N. J.
    Tweddle, D. A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 103 : E31 - E31
  • [10] Tolerance and Toxicity of the PARP Inhibitor Olaparib in Older Women with Ovarian Cancer
    Dockery, L.
    Tew, W.
    Moore, K.
    Ding, K.
    [J]. GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 197 - 198
12345